Related Experiment Video
Updated: Feb 5, 2026

Novel Passive Clearing Methods for the Rapid Production of Optical Transparency in Whole CNS Tissue
Published on: May 8, 2018
Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma
Lisa Modelevsky1, Richard Tizon1, Samantha N Reiss1
1Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA.
Aim:
To establish the safety and feasibility of rapidly infusing rituximab over 90 min in patients with primary CNS lymphoma (PCNSL).
Patients & Methods:
We retrospectively reviewed all patients with PCNSL who received rapid rituximab infusions (RRI) from January 2016 to January 2017. Primary end point was incidence of infusion reactions.
Results & Conclusion:
11 patients received a total of 44 RRIs. Rituximab was dosed at 500 or 750 mg/m2. Premedication included acetaminophen and diphenhydramine. No infusion reactions occurred during any RRI. Two infusions were administered with steroids for neurologic symptoms at baseline (4.5%). Rapid administration of rituximab was safe and feasible for patients with PCNSL and at the higher doses received.
More Related Videos
14:04Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
Published on: March 25, 2016
06:41Mouse Microsurgery Infusion Technique for Targeted Substance Delivery into the CNS via the Internal Carotid Artery
Published on: January 31, 2017
Related Concept Videos
CNS Depressants: Alcohol and Nicotine
CNS Depressants: Barbiturates and Benzodiazepines
CNS Stimulants: Psychedelic Agents
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
One-Compartment Model: IV Infusion
The one-compartment model for IV infusion uses mathematical equations to describe the rate of change in drug quantity in the body. At steady-state or infusion equilibrium, the drug input...
Two-Compartment Open Model: IV Infusion
The model illustrates the decrease in plasma drug concentration from the central compartment with a specific equation. It shows that under steady-state conditions, the drug's input rate...